10 potentially practice-changing studies from San Antonio Breast Cancer Symposium

This year’s virtual San Antonio Breast Cancer Symposium featured hundreds of abstracts that spotlighted advances in basic, translational and clinical research.

Healio and HemOnc Today present this recap of 10 potentially practice-changing studies presented at this year’s conference.

Mammogram images of breasts of a female patient. — *Source: Adobe Stock.*

Symptoms such as pain, fatigue and pruritus often went underrecognized among patients with breast cancer treated with radiotherapy. Black patients and younger patients appeared at significantly higher risk for symptom underrecognition. Read more.
Menopausal status may determine which women with lymph node-positive early breast cancer and low recurrence scores require adjuvant chemotherapy. Read more.
Breast cancer survivors of childbearing age appeared considerably less likely than women in the general population to become pregnant. Survivors who conceived after completing treatment faced elevated risks for certain complications, but most survivors who became pregnant had healthy babies. Read more.
Circulating tumor cell assessments a month after treatment initiation predicted survival among patients with metastatic breast cancer. Read more.
Women with breast cancer who underwent mastectomy and reconstructive surgery may be at increased risk for new chronic persistent use of opioids or sedative-hypnotic drugs. Read more.
The omission of radiation therapy after breast-conserving surgery did not affect survival among certain older women with early breast cancer. Read more.
Extended follow-up of a randomized phase 3 trial showed the addition of abemaciclib (Verzenio, Eli Lilly) to endocrine therapy continued to benefit certain patients with high-risk breast cancer. Read more.
More patients presented with more advanced-stage and aggressive types of breast cancer during the beginning of the COVID-19 pandemic compared with the same period in 2019. Read more
The addition of 1 year of palbociclib (Ibrance, Pfizer) to endocrine therapy failed to improve invasive DFS among women with hormone receptor-positive, HER2-negative high-risk breast cancer. Read more.
Two behavioral intervention programs appeared to effectively reduce depression symptoms among a cohort of young breast cancer survivors. Read more.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Coverage

San Antonio Breast Cancer Symposium

Read more

10 potentially practice-changing studies from San Antonio Breast Cancer Symposium

Related Content